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ABSTRACT 
We tested the efficacy of mifepristone, a glucocorticoid (GC) receptor antagonist, on 
limiting adiposity rebound and preserving whole-body insulin sensitivity following the 
cessation of daily exercise and caloric restriction (CR). We calorically restricted male 
Sprague-Dawley rats and provided 24hr access to voluntary running wheels for three 
weeks followed by locking of the wheels and reintroduction to ad libitum feeding either 
with or without mifepristone (80 mg/kg/day) for one week. Cessation of daily running 
and CR increased HOMA-IR, visceral adipose mass as well as glucose and insulin area 
under the curve during an oral glucose tolerance test versus exercising rats (p<0.05). 
These findings were prevented or attenuated by daily mifepristone treatment during the 
post-wheel lock period. These findings suggest that elevations in GC action following 
regular exercise and CR promote rapid deterioration in metabolic control in healthy 
organisms and that this phenomenon can be inhibited by the GC receptor antagonist 
mifepristone. 
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INTRODUCTION                                           1 
Being overweight or obese are substantial risk factors for increasing mortality and 
morbidity due to cardiometabolic disease. Unfortunately, epidemiological studies have 
demonstrated that the prevalence of excess body weight has increased globally over the 
past 30 years (1, 2). Additionally, a paralleled rise in obesity-related pathologies 
including impaired fasting glucose and type 2 diabetes mellitus has occurred (3). An 
important contributor to the development and progression of these conditions is physical 
inactivity. Currently is it estimated that 31% of the world’s population is not meeting 
physical activity recommendations (4). A sedentary lifestyle can lead to cardiovascular 
disease, type 2 diabetes, colon and breast cancer, dementia and depression. This 
clustering of diseases has been termed the ‘diseasome of physical inactivity’ (5), which 
has been directly related to 6-14% of all deaths from non-communicable diseases 
worldwide (6, 7). Although increased physical activity can prevent or delay such 
consequences and improve metabolic health, a key component to its success as an 
intervention is adherence. A well-documented deterioration of whole-body insulin 
sensitivity, glucose tolerance, and visceral fat mass rebound occurs rapidly following 
reduced physical activity in humans (8-13) and rodents (14-19). This strongly supports 
the notion that regular physical activity is critical in improving or maintaining health. It 
also provides insight into possible physiological reasons behind the difficulty that 
overweight and obese individuals often face when attempting to lose weight or maintain 
weight loss in the long term. Although these rapid detrimental repercussions of reducing 
physical activity have been identified, a unifying set of mechanisms underlying this 
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response has yet to be determined. The goal of this thesis is to explore the possibility that 
rapidly transitioning from a high to low level of daily physical activity sets the stage for 
rapid and deleterious adiposity rebound and impaired metabolic health by altering 
intracellular stress hormone metabolism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
LITERATURE REVIEW                                      2 
2.1      Physical inactivity 
Human beings are not designed to lead physically inactive lives. Prior to the 
development of agriculture and the domestication of animals, success of locating and 
obtaining food depended on physical activity (20). The supply of food was inconsistent 
(21) and ancient hunter-gatherers cycled through periods of feast and famine, which was 
interjected with necessary physical activity (22). In this setting, it is believed that the 
human genome evolved to ensure metabolic adaptations that corresponded to this cyclical 
environment (23). Thus, to ensure survival, triacylglycerol (TG) synthesis was 
maximized during feast periods to ensure optimal storage in adipose tissue for the 
subsequent prolonged periods of fasting. In today’s society, sedentary lifestyles and easy 
access to calorically-dense foods have been proposed to stall the feast-famine cycle and 
favour an even larger and possibly unhealthy storage of fuel (22). An unhealthy 
accumulation of fuel storage which is not abated by subsequent physical activity or 
famine may precipitate the development of chronic disease (22). Two factors which are 
believed to play important roles in the progression of chronic disease due to physical 
inactivity and poor dietary habits are insulin resistance and visceral adiposity. 
2.1.1      Insulin Resistance 
Insulin resistance and glucose intolerance are linked to obesity and metabolic 
syndrome (MetS) and are hallmarks in the progression towards the development of type 2 
diabetes. Because insulin resistance is an antecedent event in the progression from 
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metabolic impairments to overt type 2 diabetes it is often measured to assess risk and to 
guide management in both research and clinical settings (24). It has been suggested that 
the link between obesity and insulin resistance is causal (25). The rationale for this 
connection comes from both human and rodent studies demonstrating that loss and gain 
of weight correlate well with improvement and impairment of insulin sensitivity, 
respectively (26-28). However, the well-documented existence of metabolically healthy 
obese (MHO) and metabolically obese normal weight (MONW) (29, 30) individuals adds 
a puzzling complexity to the relationship between insulin sensitivity and body weight. As 
will be discussed in greater detail later, a substantial contributor to the development of 
insulin resistance is visceral adiposity (31). 
2.1.1.1      Bed rest studies 
Numerous studies have demonstrated impairments to insulin sensitivity (whole-
body and skeletal muscle), after acutely lowering daily physical activity. In humans, 
following three to ten days of bed rest in both trained and untrained healthy subjects there 
is an increase in fasted blood glucose and insulin levels, homeostasis model assessment 
for insulin resistance (HOMA-IR), as well as insulin and glucose AUC in response to an 
oral or intravenous glucose tolerance test (11-13). To help understand the mechanisms 
behind these deleterious effects, researchers have conducted hyperinsulinemic-
euglycemic clamps and reported reductions in both whole-body and leg glucose uptake 
following short-term bed rest (32, 33). This coincides with reports of a 16-17% reduction 
in glucose transporter 4 (GLUT4) content in the gastrocnemius and vastus lateralis 
muscles of healthy men following six to nineteen days of bed rest (34, 35). Evidence also 
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suggests that following acute bed rest the liver remains sensitive to insulin, as no changes 
are found in rate of hepatic glucose production in response to insulin stimulation 
compared to pre-bed rest values in the same individuals (33). Thus, the changes that 
occur to insulin sensitivity following acute bed rest are tissue-specific and skeletal muscle 
may be the most substantially affected tissue. 
2.1.1.2      Reduced step count studies 
Studies conducted with a less extreme reduction of physical activity have utilized 
reduced ambulation rather than inducing strict bed rest. Importantly, similar metabolic 
responses have been found. These reduced-ambulation studies in free-living adults are 
considered to be more representative of realistic fluctuations in daily activity, since 
individuals do not typically transition to chronic bed rest. Thus, data from reduced-
ambulation studies may be most informative of realistic changes to human health. 
Although guidelines for physical activity commonly recommend ≥ 10,000 steps daily 
(36), the mean number of steps taken daily by non-exercising American adults is 
approximately 6,000 ± 1,200 (37). Appropriately, a sudden shift in daily ambulation from 
the upper end of the spectrum (~10,000 steps) to the lower end (~2,000 steps) is 
considered to be the most insightful model of simulating sedentary behaviour in humans. 
Acutely transitioning from ≥ 10,000 to 1,500-5,000 steps for 3 to 14 days in healthy 
humans results in an increased AUC for insulin and c-peptide following an oral glucose 
challenge (8, 9), increased post-prandial glucose (PPG) following a mixed meal (8), a 
17% reduction in glucose infusion rate during a hyperinsulinemic-euglycemic clamp, as 
well as a reduced insulin-stimulated pAkt
thr308
/total Akt ratio (10). Importantly, elevated 
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PPG has been recognized as a stronger risk factor for adverse cardiovascular 
complications and all-cause mortality than both fasting glucose and hemoglobin A1c 
(HbA1c) (38, 39). 
2.1.1.3      Rodent wheel lock studies 
Dr. Frank Booth and colleagues have pioneered the ‘wheel lock’ model to study 
the metabolic impairments that ensue following reduced daily physical activity in 
rodents. This model involves giving rodents access to voluntary running wheels, which 
they exercise on intermittently throughout the day, typically running from 2-20 
kilometers per 24 hours for three to six weeks (14-19). The wheels are then locked and 
the transition from regular daily wheel running to sedentary behaviour is studied from a 
metabolic perspective. Although the daily running distances in these rodents can be 
extensive, it is being performed entirely voluntarily and it is argued that voluntary wheel 
running in rodents is relatively comparable to the upper end of the spectrum for daily 
ambulatory activity in humans (40). Impressively, only 53 hours into the wheel lock 
period after having exercised daily for three weeks, there is a (~40%) reduction in 
insulin-stimulated 2-deoxyglucose uptake by the epitrochlearis muscle versus rats that 
had their wheels locked for only 5 hours. Surprisingly, the 53 hour wheel lock group had 
2-deoxyglucose uptake values that were comparable to those of rats that had never 
exercised. Thus, the improvement in insulin sensitivity gained from daily exercise for 
three weeks is lost within the first few days following the cessation of daily exercise. This 
reduction in glucose transport coincided with 29 to 34% reductions in insulin receptor 
(IR) protein, IR
tyr
 phosphorylation, Akt
ser473
 phosphorylation, as well as GLUT4 protein 
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content (19). Interestingly, it has been demonstrated that isolated epididymal adipocytes 
retain their insulin sensitivity at 29 and 53 hours following wheel lock in rats (14). Thus, 
similar to data from humans, insulin signalling is impaired in a tissue-specific manner 
shortly following a transition to reduced levels of daily physical activity. Skeletal muscle 
insulin sensitivity appears to be the most rapidly impaired in this model, whereas adipose 
tissue insulin sensitivity is not altered in the short-term. This selective insulin resistance 
in skeletal muscle and retained insulin sensitivity in adipose tissue, in combination with 
hyperglycemia and hyperinsulinemia, may underlie the skeletal muscle atrophy and 
adipose mass growth following cessation of regular voluntary wheel running. To date, no 
studies have directly measured liver insulin sensitivity using the wheel lock model. 
However, data from humans investigating acute physical inactivity indicate that the liver 
does not become insulin resistant quickly after the initiation of sedentary behaviour 
whereas the skeletal muscle does (33). 
Ultimately, whole-body and skeletal muscle insulin sensitivity, as well as glucose 
tolerance, are consistently compromised following reductions to daily physical activity in 
both humans and rodents. This strongly indicates that fluctuations in daily physical 
activity significantly contribute to the day-to-day maintenance of proper glycemic 
control. For example, a single bout of running or cycling for 45 minutes following ten 
days of bed rest significantly improves and nearly restores glycemic response to baseline 
measurements (41). Thus, there is a substantial plasticity of insulin sensitivity and 
glucose tolerance in response to changes in physical activity. These and other studies 
demonstrate the ease with which healthy individuals can cycle through periods of glucose 
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tolerance and intolerance and thus be exposed to transient periods of hyperglycemia and 
hyperinsulinemia. Importantly, evidence from both healthy and type 2 diabetic humans 
suggests that extensive blood glucose oscillations can have more damaging effects than 
sustained hyperglycemia on endothelial cell function and generation of reactive oxygen 
species (42), a phenomenon known to play a significant role in the pathogenesis of type 2 
diabetes and its associated complications (43).  
2.1.2 Adiposity Tissue Depots: Subcutaneous vs. Visceral Fat 
 A large amount of subcutaneous adipose tissue has minimal to no detrimental 
metabolic effect and may even provide protection against chronic disease (44). However, 
there exists strong epidemiological evidence identifying visceral adiposity as a major risk 
factor for cardiovascular disease (45), insulin resistance (46, 47) and type 2 diabetes (48). 
Importantly, visceral fat appears to play a causative role in these metabolic abnormalities 
as its excision leads to dramatic improvements in hepatic and peripheral insulin 
sensitivity and glucose tolerance in rats (49, 50). Interestingly, transplantation of 
subcutaneous adipose tissue into the abdominal cavity improves insulin sensitivity, 
reduces body weight and total body fat and improves fasting glucose (51). These data 
indicate that it is not the location of visceral fat that matters most per se, but that there are 
distinct biological differences between visceral and subcutaneous fat depots. Indeed, 
there is great variance between gene expression profiles between visceral and 
subcutaneous depots, mostly in genes participating in glucose homeostasis, lipid 
metabolism, insulin action (52), and inflammatory cytokines (53). The purported 
mechanisms responsible for the pathophysiological effects of visceral fat growth include 
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increased release of free fatty acids (FFAs), cortisol and adipose tissue-derived cytokines 
including interleukin 1 (IL1), IL6, tumor necrosis factor alpha (TNF-α) and resistin  (54, 
55). 
Two key lifestyle factors that regulate storage, mobilization, and metabolism of 
lipids are physical activity and food intake. In a twelve week randomized controlled 
study, both supervised aerobic exercise three times weekly and a hypocaloric diet 
resulted in a significant reduction in total body fat, which was accompanied by a ~20-
30% reduction of visceral fat mass (56). Similar findings of substantial reductions to 
visceral fat mass by exercise intervention have been reported by others (57-59) and 
summarized in a meta-analysis more recently (60). However, one of the most challenging 
components of weight loss is maintenance of a reduced body mass. Following weight 
loss, weight regain to baseline values has been reported to occur in 50 to 97% of obese 
individuals within 2-5 years of the initial weight loss, and this coincided with not 
adhering to recommended physical activity guidelines (61, 62). Importantly, in response 
to physical inactivity the greatest relative increase in adipose tissue occurs within the 
visceral depots (63). Thus, the detrimental consequences of insufficient physical activity 
may be mediated or perpetuated through alterations to body fat distribution. 
2.1.2.1      Adipose mass rebound 
Altered lipid metabolism has been proposed to contribute to the rapid adiposity 
rebound that occurs following reduced physical activity (40, 62). Following two weeks of 
reducing daily step count from ~10,000 to ~1,500 in humans there is an ~7% increase in 
visceral fat and an ~3 % reduction in lean mass (9, 10). Yet, during this inactive period a 
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significant reduction in body mass index was also found (9). This suggests that the 
observed increase in visceral fat was not an indiscriminate result of being in a positive 
energy balance due to reduced physical activity. Rather, it suggests that a guided 
redistribution of energy substrates occurred, promoting the storage of excess lipids 
viscerally despite a mild (1.2 kg) total body weight loss (9). This data coincides with the 
rapid increase in visceral fat mass that also occurs following wheel lock in rodents. As 
early as 53 hours following three weeks of daily running there is an ~25% and ~50% 
increase in relative epididymal and omental fat, respectively in rats (14). Furthermore, 
daily voluntary running in rodents significantly lowers body fat percentage and total body 
fat but one week following wheel lock both indices are rapidly restored to levels found in 
animals that remained sedentary throughout the study (17). Importantly, this rapid 
visceral adipose tissue accumulation may contribute to the metabolic impairments that 
occur following reduced physical activity as excess visceral adiposity is well-established 
as a contributor to the development of cardiometabolic disease (47). 
The mechanism underlying this rapid visceral fat growth remains to be 
determined. Considering the tissue-specific alterations to insulin sensitivity shortly 
following reduced physical activity whereby adipose tissue (14) and the liver (33) remain 
sensitive to insulin whereas skeletal muscle does not, it is plausible that in combination 
with hyperglycemia and hyperinsulinemia this may directly contribute to a rapid increase 
in adipose tissue as well as liver lipid content. Interestingly, despite a rapid up-regulation 
in precursors which lead to increased lipid content including fatty acid synthase, acyl-
CoA carboxylase and malonyl-CoA, there is no significant increase in liver triglyceride 
11 
 
content one week following cessation of voluntary wheel running in Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats (64). This coincides with data from an earlier report 
which found that eight weeks of treadmill running followed by two weeks of sedentary 
behaviour did not significantly increase liver TG content in female Sprague-Dawley rats 
versus rats that had remained sedentary throughout the study (65). However, an increase 
in liver lipid content was found in the same study following six weeks of sedentary 
behaviour (65). Thus, the immediacy and type of physiological response to reduced 
physical activity is tissue-specific whereby the skeletal muscle rapidly develops 
resistance to insulin, a fatty liver develops over the course of several weeks and adipose 
mass grows substantially within days. 
2.1.2.2      Lipogenesis, adipogenesis, and lipid oxidation 
An identified mechanism underlying adiposity rebound in both humans and 
rodents includes an increased rate of lipid synthesis. In untrained healthy humans, one 
month of bed rest results in a 35% increase in plasma TG concentrations following a 
standardized meal versus lean untrained controls (66). Additionally, a larger 2- to 4-fold 
increase in post-prandial whole-body lipogenesis occurs within one week following bed 
rest (67). In rodents, as early as 10 hours following wheel lock, there is a ~3- to 4-fold 
rise in epididymal TG synthesis when compared to sedentary animals, and this elevated 
synthesis remains until 53 hours post-WL (14). This parallels findings of a 47% increase 
in plasma TG as well as a ~3-fold and 48% increase in mitochondrial glycerol-3-
phosphate acyltransferase (mtGPAT) expression and activity, respectively, 10 to 53 hours 
post-WL (15). The protein mtGPAT is crucial for the acylation of glycerol-3-phosphate 
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to lysophosphatidic acid and subsequent TG synthesis (68). Thus, there appears to be a 
rapid increase in lipid synthesis immediately following initiation of sedentary behaviour 
and these elevations can persist when sedentary behaviour is prolonged. Interestingly, the 
main contribution to this immediate (≤ 53 hours) adiposity rebound in wheel-locked 
rodents was mediated by an 18% increase in mean adipocyte cell volume as opposed to 
increased cell number (15). However, more recent studies that have tracked the wheel 
lock period for up to one week, reported that the rapid increase in epididymal, omental, 
retroperitoneal, as well as perirenal fat mass was primarily due to hyperplasia of 
adipocytes rather than hypertrophy (16, 18). Of particular relevance to this thesis project, 
the process of adipogenesis is critically regulated by glucocorticoids (69, 70) and the 
release of these stress hormones, or the activation of them within certain cells, may play 
an important role in the rapid deterioration of metabolic health and adipose tissue growth 
following cessation of regular exercise. 
To date, most studies investigating changes to lipid oxidation following reduced 
physical activity have focused on either whole-body or skeletal muscle measurements. A 
robust 2.5-fold reduction in fat/carbohydrate oxidation ratio and a ~90% reduction in 
basal whole-body lipid oxidation have been found in both men and women seven days 
into bed rest (67). After 1 month of bed rest a significant ~30% reduction in whole-body 
lipid oxidation remains following a standardized meal (66, 71). This coincided with 
significant reductions in cluster of differentiation 36 (CD36), lipoprotein lipase (LPL), 
carnitine palmitoyltransferase 1 (CPT1), fatty acid transport protein 1 (FATP1) mRNA, 
as well as reduced CD36 protein within the vastus lateralis (66, 71). These molecular 
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factors contribute to either the hydrolysis or uptake of lipids and thus a reduction in their 
content may contribute downstream to the impaired capacity for fat oxidation in skeletal 
muscle that follows reduced daily physical activity. It remains to be determined if there is 
an alteration in lipolysis/lipid oxidation rates within adipose tissue following cessation of 
regular exercise. However, given the robust visceral adipose mass accretion that occurs 
after the end of regular exercise, it is likely that rates of lipogenesis and adipogenesis 
dominate over lipid breakdown. 
An important shortcoming to some of these studies is that food intake following 
reduced physical activity is often not controlled. Kump & Booth (14) allowed ad libitum 
feeding throughout six weeks of voluntary wheel running as well as during the sedentary 
wheel lock period and found that exercised rodents ate more than sedentary animals 
throughout the protocol. Thus, it was uncertain if the increased adipose mass was due 
solely to a reduction in physical activity or was contributed to by excess caloric intake. 
To test the hypothesis that inactivity, independent of caloric intake, could induce an 
increase in fat pad mass, a follow-up study used two sets of wheel-locked animals: a) 
given ad libitum access to food and b) pair-fed to match sedentary controls.  Importantly, 
pair-feeding throughout the study did not prevent the adipose mass gain. A significant 34 
and 91% increase in epididymal and retroperitoneal fat, respectively, still occurred one 
week after wheel lock when compared to rats that were euthanized 5 hours after wheel 
lock (16). Thus, it appears that cessation of regular exercise directly contributes to 
adiposity rebound in this model. 
2.2      Glucocorticoids 
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2.2.1      Synthesis, secretion and action 
GCs are a class of steroid hormones that are endogenously secreted in both a 
stress-induced and circadian fashion from the adrenal cortex and are the end-product of 
the hypothalamic-pituitary-adrenal (HPA) axis. Stimulation of the HPA axis first results 
in the secretion of corticotropin-releasing hormone (CRH) from the paraventricular 
nucleus within the hypothalamus. CRH travels into the hypophysial portal system to the 
anterior pituitary and stimulates the release of adrenocorticotropic hormone (ACTH). 
Once secreted into the blood, ACTH travels to the adrenal glands and ultimately causes 
the synthesis and release of GCs (cortisol in humans and corticosterone in rodents). GC 
secretion is pulsatile and circulating concentrations are highest in the morning and lowest 
in the evening in diurnal mammals. In contrast, nocturnal mammals have their nadir in 
the morning and highest levels in the evening. GCs circulate systemically and regulate 
many biological functions including metabolism, development, growth and apoptosis 
(72). Because GCs are steroid derived hormones and thus lipophilic, they circulate 
predominantly bound to carrier proteins, including cortisol binding globulin and albumin 
(73, 74). Only unbound or ‘free’ GCs are able to enter cells and this is completed by 
passively diffusing across cell membranes. Once inside a cell, active GCs bind to the 
glucocorticoid receptor (GR), which induces a conformational change and leads to the 
dissociation of accessory proteins including heat shock proteins and immunophilins (75). 
This GC-bound GR then translocates to the nucleus where it may interact either directly 
or indirectly with DNA via GC response elements or transcription factors, respectively. 
Once the GR binds to the targeted region of DNA it will either increase (transactivation) 
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or decrease (transrepression) gene transcription (76). GCs are primarily catabolic in 
action and as such, the genes which they activate primarily regulate hepatic 
gluconeogenesis, muscle proteolysis, as well as adipose tissue lipolysis (77) (Figure 1) 
(see a further discussion on GCs and lipolysis below). Local tissue exposure depends on 
circulating concentrations of GCs, the level of expression of GRs, as well as on the 
activity and content of the pre-receptor enzyme 11β-HSD1. This enzyme catalyzes the 
conversion of inactive cortisone to active cortisol in humans and is expressed in a variety 
of tissues including the liver, adipose tissue and skeletal muscle (78). The counterpart, 
11β-HSD2, is located primarily in the distal nephron of the kidney and catalyzes the 
conversion of active cortisol to inactive cortisone in humans to protect against GR 
binding with the mineralocorticoid receptor to have aldosterone-like renal effects (78). 
2.2.2      Actions on Lipolysis 
Adipose tissue is the body’s largest reservoir of energy and it plays a crucial role in the 
regulation of energy homeostasis. During periods of energy deprivation or greater energy 
expenditure such as caloric restriction or exercise, respectively, adipocytes favor 
hydrolysis rather than storage of TGs (Figure 2A). Subsequently, adipocytes release 
FFAs for oxidation in other tissues such as skeletal muscle, liver, and the heart for the 
provision of energy (79). The molecular machinery of lipolysis consists primarily of three 
lipases; adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL) and 
monoacylglycerol lipase (MGL). Both ATGL and HSL are regulated by additional 
interacting proteins and secondary messengers which are primarily regulated by 
catecholamines, natriuretic peptides and insulin (80). However, glucocorticoids (GCs) 
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have also been identified as notable contributors to adipose tissue lipolysis (Figure 2A). 
What limits the status of GCs as a major regulator of lipolysis is the inconsistency of their 
effects. This inconsistency has been attributed to the duration of exposure, the 
concentration, the experimental model used, as well as the type of GC (81, 82). Twenty-
four to 48 hours of exposure to dexamethasone, cortisone, cortisol and corticosterone 
have all shown to increase lipolysis in mature adipocytes (83, 84). This occurs in tandem 
with increased mRNA expression of ATGL and total HSL as well as increased content of 
ATGL and greater phosphorylation of HSL on the activating sites Ser563 and Ser660 (83, 
84). Additionally, the activity of protein kinase A (PKA) and cyclic adenosine 
monophosphate (cAMP) content are also elevated following 24 hours of exposure to 
dexamethasone. This occurs with a concurrent reduction in the expression of the cAMP-
inhibitor phosphodiesterase 3B (PDE3B). Lastly, this group also found that 
dexamethasone reduced the content and increased phosphorylation of perilipins in a dose- 
and time-dependent manner (84). While catecholamines rapidly induce lipolysis (acting 
within seconds to minutes), the lipolytic action of glucocorticoids takes several hours. An 
increase in FFA and glycerol release has been found as early as 16 hours following 
dexamethasone administration in isolated rat adipocytes (84) and within 6 hours in 
humans infused with hydrocortisone (85, 86). Importantly, GC-induced lipolysis is 
abolished by co-treatment with the GR antagonist mifepristone (83, 84). Thus, the action 
of GCs on lipolysis is a delayed response that acts through the GR, regulates the 
expression and protein content of lipolytic enzymes and ultimately becomes significant 
only after several hours of exposure. This is supported by data showing that GCs, acting 
through the GR, regulate the expression of the transcription factors peroxisome  
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Figure 1. Glucocorticoid physiology. In response to a stressor the hypothalamus 
secretes CRH which leads to a cascade of ACTH from the anterior pituitary followed by 
GCs (cortisol in humans) secretion from the adrenal cortex. Cortisol enters cells via 
passive diffusion and bind to the GR. The GR may then translocate to the nucleus, bind to 
glucocorticoid response elements and alter the mRNA expression of its target genes. GCs 
induce gluconeogenesis, fatty acid mobilization and proteolysis. The ultimate effect is an 
elevation of blood glucose levels and metabolites which can be used for the provision of 
energy. 
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Figure 2. Glucocorticoids, exercise and caloric restriction affect lipid turnover. (A) 
Regular exercise and caloric restriction lead to increases in fat mobilization from adipose 
tissue by increasing the content and activity of glucocorticoid-inducible lipolytic proteins 
and limiting the antilipolytic effect of insulin. Regular exercise increases 11β-HSD1 
content and thus intracellular GC exposure (B) Cessation of regular exercise and 
reintroduction to ad libitum food intake lead to a rapid increase in visceral fat mass, 
impaired glucose tolerance and whole-body insulin sensitivity. Rapid adipose tissue 
growth is believed to be due to inhibition of lipolysis and stimulating of lipogenesis 
which is exacerbated hyperinsulinemia due to the development of insulin resistance. 
Sustained elevations in GC exposure stimulate hyperplasia of visceral adipose tissue. 
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proliferator-activated receptor gamma 1 and 2 (PPARγ1 and PPARγ2) (86), which 
regulate the mRNA expression and protein content of ATGL both in vivo and in vitro 
(87). 
Individuals with Cushing’s syndrome have been documented as having a higher 
rate of lipolysis in adipose tissue than healthy subjects (88). A consequence of this, 
especially relevant under the threat of chronic exposure to GCs, is an increased efflux of 
FFAs from adipocytes that can both induce and exacerbate liver and whole-body insulin 
resistance (89, 90). Despite the clear impact that GCs can have on increasing the potential 
for lipolysis by increasing lipase expression, their precise roles in vivo remain conflicting 
as they have also been shown to increase adipogenesis and lipogenesis in adipose tissue. 
In support of this, ten days of treatment with corticosterone in Sprague-Dawley rats has 
been shown to significantly increase epididymal adipose mass despite an increased rate of 
basal lipolysis in isolated adipocytes. Interestingly, these rodents also exhibited a 60% 
reduction in visceral adipocyte size and a 2.5-fold increase in number of adipocytes per 
mg of tissue, suggesting hyperplasia as the major contributor to adipose mass growth 
(83). These findings are in contrast to four weeks of dexamethasone treatment in Wistar 
rats which resulted in increased adipocyte diameter, suggesting hypertrophy (91).  The 
discrepancies between these studies may be due to the type of GC used, the duration of 
exposure, or the different rodent models. Thus, GCs are capable of concurrently inducing 
lipolysis and a growth in adipose tissue mass which may be contributed to by 
hypertrophy and/or hyperplasia. 
2.2.3      Conditions/consequences of excess glucocorticoid exposure 
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2.2.3.1      Cushing’s syndrome 
First described by Harvey Cushing in the beginning of the 20
th
 century (92), 
Cushing’s disease is caused by overproduction of ACTH due to a tumor on the pituitary 
gland and it is the most common cause of Cushing’s syndrome (93). Cushing’s syndrome 
refers to a pathological excess of GCs in the body, regardless of the cause. Excess 
exposure to GCs, as is found in individuals with Cushing’s syndrome, leads to glucose 
intolerance, hypertension, muscle wasting and central adiposity growth (94). 
The primary goals of treating Cushing’s syndrome include elimination of 
hypercortisolism, reversal of comorbidities, and long term disease control (93). The first-
line treatment of choice is trans-sphenoidal pituitary surgery where the ACTH-secreting 
adenoma is removed. Second-line treatments are comprised of radiotherapy, bilateral 
adrenalectomy, and medical therapy. Radiotherapy is a well-established therapy used in 
cases of recurrent or persistent Cushing’s syndrome or where surgery is contraindicated. 
However, the greatest weaknesses of this therapeutic strategy are the substantial risk of 
hypopituitarism (93) and the mean time to remission being 2-3 years (95, 96). In contrast, 
bilateral adrenalectomy is a permanent treatment that provides immediate control of 
hypercortisolism. However, this option is recommended only in patients with intolerance 
to medical therapy, sustained hypercortisolism despite medical therapy, or as an 
alternative to long-term medical therapy after failure of radiotherapy (93). Patients 
undergoing this procedure resultantly require life-long glucocorticoid and 
mineralocorticoid replacement therapy (97).  
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Medical therapy for Cushing’s syndrome is mostly advised in patients who are 
either awaiting the full benefits of radiation therapy to take effect, in need of better 
control of their hypercortisolism prior to surgery, or have ACTH-dependent 
hypercortisolism where surgery is contraindicated due to unknown origin of the tumor 
(98). Medications includes inhibitors of steroidogenesis which act by blocking one or 
multiple steps in glucocorticoid synthesis, neuromodulatory agents which inhibit ACTH 
secretion from the pituitary gland, as well as the type II GR antagonist mifepristone (also 
known by the names RU486 and Korlym™) (98). 
2.2.3.2      Metabolic syndrome and obesity 
MetS is a cluster of disease characteristics that are associated with insulin 
resistance and include hypertension, dyslipidemia, hyperglycemia and abdominal obesity 
(99). Although various health organizations have defined MetS differently (100), it 
remains a useful tool in identifying individuals at a greater risk of developing both 
cardiovascular disease and type 2 diabetes.  One of the most widely used definitions is 
the one from the National Cholesterol Education Program (NCEP) Adult Treatment 
Panel-III (ATP-III). According to this definition, MetS is diagnosed when at least three of 
the following criteria are met: blood pressure  ≥130/85 mmHg, high-density lipoprotein 
(HDL) <1.04 mM in men and <1.29 mM in women, TG ≥ 1.7 mM, fasting glucose ≥ 6.1 
mM, and a waist circumference >102 cm in men and >88 cm in women (101). One of the 
major drawbacks to the current MetS definitions is that they do not directly encompass 
visceral adiposity. Although waist circumference is a better predictor of metabolic 
disease than body mass index, it is unable to distinguish between visceral and 
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subcutaneous fat. Importantly, visceral obesity has become increasingly recognized as the 
most prevalent feature underlying insulin resistance and MetS (102-104). However, the 
mechanisms that link causality between visceral obesity and MetS are not fully 
understood.  
A striking similarity of metabolic abnormalities exists between individuals with 
MetS, Cushing’s syndrome (94) or those on exogenous GC treatment (105). These 
individuals have an increased propensity for weight gain, visceral adiposity, and type 2 
diabetes. These similarities were the basis for the hypothesis that perhaps systemic 
hypercortisolism played a significant role in the pathogenesis of MetS and obesity. 
Indeed, it has been demonstrated that circulating cortisol levels are higher in both 
overweight individuals and those with MetS versus healthy subjects (106-110).  
However, others have found no correlation between either circulating or urinary free 
cortisol in obese individuals (111-115).  
An additional component which contributes to tissue exposure to GCs, 11β-
HSD1, has become a target of much research as it is capable of increasing GC activity in 
the periphery despite any change to circulating concentrations. This effect has been 
labelled ‘Cushing’s disease of the omentum’ (116). Furthermore, recent data suggests 
that this enzyme may be the major regulator of tissue-specific effects of excess GC 
exposure. It was found that adipose-specific 11β-HSD1 knockout (KO) mice 
administered corticosterone in their drinking water were resistant to developing glucose 
intolerance, hypertension, hyperinsulinemia, hepatic steatosis, and increased adiposity 
(117). 
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2.2.3.3      11β-hydroxysteroid dehydrogenase type 1 
The enzyme 11β-HSD consists of two isoforms each with distinct functions. 11β-
HSD1 is a low-affinity nicotinamide adenine dinucleotide phosphate (NADPH)-
dependent reductase expressed in key metabolic tissues including adipose tissue, muscle, 
and liver. 11β-HSD1 is positioned within the endoplasmic reticulum membrane. It 
catalyzes the generation of active GCs by reducing cortisone to cortisol (in humans) in 
the cytosol and oxidizing NADPH to NADP
+
 within the ER lumen (118). The cofactor 
NADPH is generated within the lumen by the enzyme hexose-6 phosphate 
dehydrogenase during the conversion of glucose-6-phosphate to 6-
phosphogluconolactone (Figure 3).  This process leads to an amplification of intracellular 
active GC exposure. In contrast, 11β-HSD2 is a high-affinity nicotinamide adenine 
dinucleotide (NAD
+
)-dependent dehydrogenase, expressed primarily in mineralocorticoid 
target tissues including sweat and salivary glands, colonic epithelium, and the distal 
nephron, that catalyzes the reverse reaction resulting in the conversion of active GCs to 
their inert 11-keto acid forms, thereby reducing intracellular exposure (78). 
2.2.3.3.1      Adipose tissue overexpression 
Evidence has been accumulating for nearly 20 years in support of a role of 11β-HSD1 in 
the pathogenesis of MetS and visceral obesity in particular. An early paper investigating 
this topic of intracellular hypercortisolism discovered that 11β-HSD1 is more abundant in 
omental than subcutaneous fat (116). Additionally, 11β-HSD1 mRNA, protein, and 
activity are significantly greater in visceral adipose tissue from obese humans and rodents 
compared to lean individuals (119, 120). This is suggestive of a role of local GC 
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amplification in the pathogenesis of obesity and MetS. In accordance with this, selective 
adipose tissue overexpression of 11β-HSD1 in mice results in the development of many 
features of MetS including insulin resistance, glucose intolerance, dyslipidemia, 
hypertension and visceral obesity (121, 122). Under the control of the adipocyte fatty 
acid-binding protein (aP2) promoter, these mice present with a mild 2- to 3-fold increase 
in 11β-HSD1 activity exclusively within adipose tissue. Importantly, this increase is 
comparable to that found in obese humans and is thus a physiologically relevant model 
(123). These mice are obese and hyperphagic, have significantly increased serum TG, 
increased adipose lipoprotein lipase gene expression, serum TNF-α, and elevated portal 
vein corticosterone and FFAs (121). This portal drainage of elevated FFAs and 
corticosterone is believed to contribute to the development of hepatic insulin resistance 
(124). 
2.2.3.3.2      Liver overexpression 
The phenotype of mice overexpressing 11β-HSD1 exclusively within the liver 
diverges from that of the aP2 promoter model. This model is under the control of the 
human apolipoprotein E (apoE) promoter and results in a 2- to 5-fold elevated hepatic 
11β-HSD1 activity. Interestingly, these mice present with milder systemic insulin 
resistance and remain glucose tolerant. They develop dyslipidemia, hepatic steatosis, and 
hypertension, but demonstrate no difference in adipose tissue mass when compared to 
wild type mice (125). These data suggest that elevated 11β-HSD1 hepatic expression may 
relate to the pathogenesis of fatty liver, hypertension, and insulin resistance, although 
without obesity as may occur in MONW individuals. The difference in capacity to induce  
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Figure 3. Generation of active GCs by 11β-HSD1. 11β-HSD1 has oxoreductase 
activity and catalyzes the conversion of inactive cortisone to active cortisol in humans 
(11-dehydrocorticosterone to corticosterone, in rodents). Generation of active cortisol 
occurs via the reduction of cortisone to cortisol in the cytosol and oxidization of NADPH 
to NADP
+
 within the ER lumen (118). The cofactor NADPH is generated within the 
lumen by the enzyme hexose-6 phosphate dehydrogenase (H6PDH) during the 
conversion of glucose-6-phosphate (G6P) to 6-phosphogluconolactone (6PG).  This 
process leads to an amplification of intracellular exposure to active GCs. 
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obesity suggests that adipose tissue exposure to GC has a greater impact on energy-
homeostasis than the liver. 
Although 11β-HSD1 is more abundant in intra-abdominal compared to 
subcutaneous depots (116) and the subsequent pathophysiological consequences are well-
established, evidence suggests that increased 11β-HSD1 mRNA, protein, and activity in 
subcutaneous fat also has a positive correlation with BMI, fasting insulin, and visceral 
and total body fat (126, 127). Furthermore, 11β-HSD1 content in skeletal muscle also 
appears to be an important regulator of glucocorticoid-induced insulin resistance (128). 
Thus, there are multiple tissues that are detrimentally affected by increasing 11β-HSD1 
content. However, the relative contribution towards developing MetS remains 
incompletely understood. 
2.2.3.3.3      Knockout studies 
  Due to the strong connection between 11β-HSD1 activity and features of MetS, 
inhibition of local GC production has become a desirable therapeutic target. Over the past 
twenty years genetic studies investigating 11β-HSD1 knockout have found that these 
rodents display a reduced risk for the development of obesity and MetS. Mice with global 
11β-HSD1 deletion secrete increased amounts of corticosterone and ACTH, develop 
adrenal hyperplasia, and upon fasting they have attenuated activity of the gluconeogenic 
enzymes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase (129, 130). 
Compared to wild type mice they also present with reduced plasma TG, increased HDL, 
and enhanced glucose tolerance even on a chow diet (131). When placed on a high-fat 
diet, these knockout mice are resistant to becoming obese (132). Following eighteen 
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weeks of high fat feeding, 11β-HSD1 KO mice accumulate less visceral fat and do not 
gain as much body weight despite greater food intake. In addition, they are protected 
from development glucose intolerance and maintain greater insulin sensitivity Moreover, 
11β-HSD1 KO resulted in elevated adipose tissue gene expression of adiponectin, 
PPARγ, and uncoupling protein-2 (UCP-2), as well as reduced adipose tissue gene 
expression of resistin and TNF-α, suggesting greater adipose tissue insulin sensitivity and 
energy dissipation (132). Similarly, adipose tissue-specific inactivation of GCs by 
overexpression of 11β-HSD2 also protects against high-fat diet-induced obesity (133). 
Following twenty-one weeks of high-fat feeding, these transgenic mice exhibited 
increased gene expression of adiponectin, PPARγ and UCP2, and reduced resistin (133). 
Thus, reduced intracellular exposure to active GCs by either 11β-HSD1 knockout or 
overexpression of 11β-HSD2 lead to and increased ratio of insulin-sensitizing to 
desensitizing factors. Furthermore, both 11β-HSD1 KO and 11β-HSD2 overexpression 
protected against the development of glucose intolerance and insulin resistance in 
response to a high-fat diet (132, 133). 
Chronic inflammation within adipose tissue has also been identified as a common 
feature of metabolic disease and obesity (134). Altered FFA and adipokine release can 
impair insulin signaling within the liver and skeletal muscle (135, 136) and is linked to 
the recruitment of proinflammatory cytokines particularly within visceral fat depots 
(137). GCs are well-known for their potent anti-inflammatory effects (138) and thus it is 
plausible that elevated 11β-HSD1 would lead to increased active GCs and subsequently 
reduce inflammation within adipose tissue. However, mice with 11β-HSD1 KO actually 
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present with reduced levels of genes participating in the differentiation, proliferation and 
adhesion of immune cells, including T cells and macrophages (139). In fact, several 
inflammatory conditions including inflammatory bowel disease, colitis, and 
atherosclerosis have been associated with increased rather than reduced 11β-HSD1 
expression (140-142). The proinflammatory cytokines TNF-α and IL1β are induced by 
nutrient excess and can subsequently induce 11β-HSD1 expression within adipocytes 
(143). Thus, inflammation may play a role in the initial augmentation of 11β-HSD1 and 
subsequently lead to local GC excess. 
2.3      Mifepristone (RU486) and 11β-HSD1 inhibitors 
Both mifepristone and 11β-HSD1 inhibitors act to block GC signaling by 
preventing GCs from binding to the GR or reducing the intracellular conversion to active 
GC’s, respectively. Mifepristone is a non-selective competitive antagonist for the GR, the 
progesterone receptor (PR), but not the mineralocorticoid receptor (144). It is able to bind 
to the GR with an affinity 4-fold greater than dexamethasone and 18-fold greater than 
cortisol (145). Upon binding, it inhibits the subsequent transcriptional activity of the GR 
and thus reduces the physiological effects of GCs. One of the first published reports of 
the clinical efficacy of mifepristone in humans was its use in a patient with Cushing’s 
syndrome. Over a nine week period, daily oral mifepristone administration resulted in the 
resolution of some consequences of their hypercortisolism including hypertension and 
hyperglycemia (146). Interestingly, this individual also had reduced central adiposity 
following treatment despite no change in body mass (146). Thus, GR antagonism appears 
to counteract the preferential redistribution of energy substrates being stored viscerally 
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due to hypercortisolism. Mifepristone also ameliorates whole-body and skeletal muscle 
insulin resistance caused by high-fat feeding (147) and exogenous GC administration in 
rats (148). These improvements are paralleled by reduced fed and fasted plasma glucose, 
fasted insulin, fasted FFAs, as well as resolution of glucose intolerance and ectopic fat 
deposition in skeletal muscle and the liver (148). More recently, mifepristone 
administration in mice fed a high-fat diet led to increased plasma content and mRNA 
expression of adiponectin from visceral fat (149). This was also paralleled by 
improvements in insulin sensitivity (149). 
Of note, GCs upregulate the expression of 11β-HSD1 mRNA in adipocytes (150), 
preadipocytes (151), and the liver (152) by acting indirectly through the transcription 
factor CCAAT/Enhancer-Binding Protein-β (C/EBP-β) (153). Mifepristone 
downregulates both the mRNA expression and protein content of 11β-HSD1 in adipose 
tissue and the liver (148, 154). Thus, mifepristone may be considered as an indirect 11β-
HSD1 inhibitor. Inhibition of 11β-HSD1 has proven to be of great benefit in rodents. The 
potent small molecule inhibitor, compound 544, binds to 11β-HSD1 with >100 and >450-
fold selectivity versus mouse and human 11β-HSD2, respectively (140). Use of this 
compound improved insulin resistance and insulin, glucagon and glucose levels in mouse 
models of type 2 diabetes (140). It also reduced body mass, visceral fat mass and serum 
lipid levels in models of diet-induced obesity and atherosclerosis. Additionally, it almost 
completely abolished the progression of aortic plaque deposition in apoE-deficient mice, 
a model of atherosclerosis (140). In humans, daily administration of the 11β-HSD1 
inhibitor INCB13739 for twelve weeks in patients with type 2 diabetes reduced HbA1c (-
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0.6%), HOMA-IR, fasting plasma glucose, and mildly reduced body mass (155). In those 
patients who were hyperlipidemic at baseline, plasma triglycerides, low density 
lipoprotein (LDL) cholesterol and total cholesterol were all reduced (155). Currently, 
there are numerous 11β-HSD1 inhibitors that are in development, with some progressing 
to phase I and II clinical studies (138). However, excitement for pharmaceutical 
development as a treatment for type 2 diabetes has diminished somewhat lately due to the 
relatively mild improvements in primary outcomes (i.e. fasting plasma glucose, blood 
pressure), complexities of 11β-HSD1 physiology, and competition from other glucose-
lowering agents on the market (156). There are also naturally occurring compounds that 
demonstrate a potent and selective capacity to inhibit 11β-HSD1. Curcumin and 
epigallocatechine-3-gallate (derived from green tea), both phenolic compounds, have 
demonstrated inhibition of rodent and human 11β-HSD1, respectively (157, 158). Daily 
administration of curcumin reduced fasted plasma glucose, triglycerides, total cholesterol 
and LDL cholesterol in obese high-fat fed rats (158). Collectively, the data from GR and 
11β-HSD1 inhibition studies indicate a great capacity to reduce cardiometabolic risk, 
symptoms of type 2 diabetes, Cushing’s syndrome, and MetS. 
2.4      Physical activity, 11β-HSD1 and glucocorticoids 
GC exposure in response to physical activity appears to be both tissue- and 
temporally-specific. A significant reduction in liver GR protein content occurs following 
seven weeks of either treadmill or swim training in rats (159, 160). Skeletal muscle 
demonstrates a reduced content in both GR as well as 11β-HSD1 in response to four 
weeks of voluntary wheel running (161). Interestingly, it appears that following two 
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weeks of exercise there is an initial increase in adrenal sensitivity to ACTH, resulting in 
significantly more circulating GCs in response to an ACTH challenge. Yet, after eight 
weeks of regular exercise this effect is attenuated and a similar response is found to that 
of sedentary rats (162). Thus, with long-term exercise there is a trend of reduced tissue 
sensitivity to GCs that may be preceded by an initial enhancement relative to sedentary 
subjects.  
Our laboratory studies the mechanisms of the protective effects of exercise on the 
development of MetS and how regular exercise affects GC signaling. Previously we have 
demonstrated in various rodent models that daily exercise increases intracellular visceral 
adipose tissue exposure to GCs, as demonstrated through elevated content and activity of 
11β-HSD1 and elevated GR protein (161, 163, 164). Importantly, excess exposure to GCs 
within adipose tissue, mediated by overexpression of 11β-HSD1, has been well 
established as an inducer of hyperinsulinemia, hyperglycemia and growth of visceral fat. 
However, the rodents from our studies remained insulin sensitive, glucose tolerant, and 
had reduced visceral adiposity. Thus, increased GC exposure within adipose tissue can be 
associated with both impaired and improved metabolic health. Booth and colleagues have 
demonstrated the rapid impairments in insulin sensitivity and growth of visceral adipose 
tissue that occurs after cessation of regular physical activity in rodents (9, 14, 16). 
Strikingly similar consequences are found in response to chronically elevated exposure to 
GCs. Thus, it is plausible that elevations in GC exposure in visceral adipose tissue, which 
appear to be non-detrimental in association with regular exercise, may predispose 
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individuals to rapid adipose tissue growth, impaired insulin sensitivity, and glucose 
intolerance once regular exercise is stopped (Figure 2B). 
2.5      Summary 
In summary, reducing daily physical activity is detrimental for metabolic health, 
although the mechanism for this deterioration in health is not entirely clear. Numerous 
studies investigating transient physical inactivity (bed rest, reduced ambulatory activity, 
cessation of regular exercise) for various lengths of treatment (3-60 days in human 
studies and 5-173 hours in rodent studies) consistently demonstrate similar metabolic 
impairments with rapid rebound in adipose mass and a rapid deterioration in skeletal 
muscle insulin sensitivity. Thus, despite the specific intervention and the debated 
relevance of each on being insightful to human health, the reproducibility and similarity 
of their consequences are striking. Additionally, these metabolic impairments are 
believed to perhaps precipitate the development of cardiometabolic disease. GCs are 
capable of stimulating lipolysis, adipose tissue growth (primarily visceral), and impairing 
metabolic health. Currently, it remains to be determined whether GCs contribute to the 
susceptibility behind this rebound adiposity phenomenon, rapid impairments in glucose 
tolerance, and insulin sensitivity that occurs following cessation of regular physical 
activity. 
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RATIONALE AND OBJECTIVES                      3 
3.1      Rationale 
The acute transition from high to low daily physical activity is an understudied 
area of research. It is well established that reducing daily physical activity results in 
impaired insulin sensitivity, glucose tolerance, and a rapid increase in visceral adiposity 
that occurs in tandem with increased rates of lipid synthesis and adipocyte hyperplasia. 
Strikingly similar findings are produced by excess exposure to GCs. Chronic exposure to 
GCs, as is found in individuals with Cushing’s syndrome, result in numerous metabolic 
impairments including but not limited to insulin resistance, impaired glucose tolerance, 
hypertriglyceridemia, and pronounced visceral obesity (121, 165, 166). Furthermore, GCs 
facilitate the process of adipogenesis; the conversion of preadipocytes to adipocytes (69, 
167, 168). 
Previously our laboratory has demonstrated in various rodent models that daily 
exercise increases intracellular visceral adipose tissue exposure to GCs, as demonstrated 
through elevated content and activity of the pre-receptor enzyme 11β-HSD1 as well as 
through elevated GR protein (161, 163, 164). Yet, these rodents remained insulin 
sensitive, glucose tolerant, and had reduced visceral adiposity. Thus, increased GCs can 
be associated with both impaired and improved metabolic health. We believe that 
sustained elevations in GC exposure in visceral adipose tissue, which appear to be non-
detrimental in association with regular exercise, may predispose individuals to the well-
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documented rapid adiposity rebound, impaired insulin sensitivity and glucose intolerance 
that occur following reduced daily physical activity. 
3.2      Objectives 
 The objectives of this thesis were to demonstrate if there is a link between GC 
exposure and the rapid deterioration of metabolic control that follows cessation of regular 
exercise. We aimed to determine if the reductions in glucose tolerance, insulin sensitivity, 
and rapid adipose tissue growth that occurs following the cessation of regular exercise 
and caloric restriction could be attenuated by using a GC receptor antagonist, 
mifepristone (RU486, Korlym
TM
), after exercise and caloric restriction is stopped.  
3.3      Hypotheses 
We hypothesized that sustained elevations in GC exposure, which appear to be 
non-detrimental in association with regular exercise, may influence the rapid adiposity 
rebound and reduction in insulin sensitivity that occurs upon cessation of regular 
exercise. Furthermore, we anticipated that blocking the action of GCs upon initiation of 
sedentary behaviour prevents, reverses, or attenuates these detrimental obesogenic 
consequences. 
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Introduction 
Overweight and obesity are substantial risk factors for increasing mortality and 
morbidity due to cardiometabolic disease. Unfortunately, epidemiological studies have 
demonstrated that the prevalence of excess body weight has increased globally over the 
past 30 years (1, 2). Additionally, a paralleled rise in obesity-related pathologies 
including impaired fasting glucose and type 2 diabetes mellitus has occurred (3). An 
important contributor to the development and progression of these conditions is physical 
inactivity. Currently is it estimated that 31% of the world’s population is not meeting 
physical activity recommendations (4). A sedentary lifestyle can lead to cardiovascular 
disease, type 2 diabetes, colon and breast cancer, dementia and depression. This 
clustering of diseases has been termed the ‘diseasome of physical inactivity’ (5), which 
has been directly related to 6-14% of all deaths from non-communicable diseases 
worldwide (6, 7). Although increased physical activity can prevent or delay such 
consequences and improve metabolic health, a key component to its success as an 
intervention is adherence. A well-documented deterioration of whole-body insulin 
sensitivity, glucose tolerance, and visceral fat mass rebound occurs rapidly following 
reduced physical activity in humans (8-13) and rodents (14-19). This strongly supports 
the notion that regular physical activity is critical in improving or maintaining health. It 
also provides insight into possible physiological reasons behind the difficulty that 
overweight and obese individuals often face when attempting to lose weight or maintain 
weight loss in the long term. Although these rapid detrimental repercussions of reducing 
physical activity have been identified, a unifying set of mechanisms underlying this 
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response has yet to be determined. The acute transition from high to low daily physical 
activity is an understudied area of research. To date, it is known that reducing daily 
physical activity results in impaired insulin sensitivity, glucose tolerance, and a rapid 
increase in visceral adiposity that occurs in tandem with increased rates of lipid synthesis 
and adipocyte hyperplasia. Strikingly similar findings are produced by excess exposure to 
glucocorticoids (GCs). Chronic exposure to GCs, as is found in individuals with 
Cushing’s syndrome, result in numerous metabolic impairments including but not limited 
to insulin resistance, impaired glucose tolerance, hypertriglyceridemia, and pronounced 
visceral obesity (121, 165, 166). Furthermore, GCs facilitate the process of adipogenesis; 
the conversion of preadipocytes to adipocytes (69, 167, 168). 
We have previously demonstrated in various rodent models that daily exercise 
increases intracellular visceral adipose tissue exposure to GCs, as demonstrated through 
elevated content and activity of the pre-receptor enzyme 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) as well as through elevated GR protein (161, 163, 
164). Yet, these daily exercised rodents remained insulin sensitive, glucose tolerant, and 
had reduced visceral adiposity. Thus, increased GC exposure can be associated with both 
impaired and improved metabolic health. We propose that sustained elevations in GC 
exposure in visceral adipose tissue, which appear to be non-detrimental in association 
with regular exercise, may predispose individuals to the rapid adiposity rebound, 
impaired insulin sensitivity and glucose intolerance that occur rapidly following reduced 
daily physical activity. 
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To study this phenomenon, a ‘wheel lock’ experimental design was used. This 
involves providing access to voluntary running wheels to rodents for several weeks 
followed by locking of the wheels for various periods of time. Booth and colleagues have 
contributed much of the existing research on this model (14-19). To date, their 
observations have paralleled many of the findings from bed rest and reduced ambulation 
studies in humans, which have documented rapidly impaired glucose tolerance, insulin 
sensitivity, and increased visceral fat accumulation (8-13). However, no attempt has been 
made to investigate how and if these impairments can be abolished during the wheel lock 
period. We hypothesized that by blocking exposure to GCs during the initiation of 
sedentary behaviour these metabolic impairments may be improved. A corollary of this 
investigation would be the elucidation of crucial intracellular signaling events that 
underlie the physical inactivity-induced impairments to metabolic health. 
Methods 
Ethics Statement 
This study was carried out in accordance with the recommendations of the 
Canadian Council for Animal Care guidelines and has been approved by the York 
University Animal Care Committee (Protocol # 2013-6). 
Rodent Treatment and Experimental Design 
Thirty-six young male Sprague-Dawley rats (Charles River Laboratories, 50-75 g 
upon arrival) were individually housed after acclimatization to a humidity (50-60%), 
temperature (22-23°C), and light-controlled (12 h: 12 h light-dark cycle) room. Rats were 
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randomly assigned to one of four different treatment groups: sedentary, control runners, 
placebo post-wheel lock (post-WL), or mifepristone post-WL (n=8-10 per group). We 
measured ad libitum food intake in sedentary rats for 28 days and found a daily average 
intake of 30.7 ± 1.7 g during this period (Supplementary Fig. 2C). For the first three 
weeks, control runners, placebo post-WL, and mifepristone post-WL were given 24 h 
access to voluntary running wheels and were placed on a calorically-restricted diet of 15 
g/day of standard rodent chow (Purina Labdiet, 5012, St. Louis, Missouri). The sedentary 
animals (normal cage ambulation) were placed on the same calorically-restricted diet. At 
the end of the third week, the placebo and mifepristone post-WL groups had their running 
wheels locked and were reintroduced to ad libitum feeding for one additional week. 
During this final week, the placebo and mifepristone post-WL groups received an oral 
gavage of either mifepristone (80 mg/kg/day) or a placebo (Vehicle). All groups were 
euthanized by decapitation; sedentary and control runners at the end of the third week for 
use as pre-wheel lock comparisons; placebo and mifepristone post-WL at the end of the 
fourth week. 
Plasma Analysis 
Plasma was isolated from blood collected via saphenous vein bleed during an oral 
glucose tolerance test to measure insulin (Cat #90060, Crystal Chem, Downer’s Grove, 
Illinois) at select time points, as well as on the morning of day 0, 10, 20 and 25 at 
approximately 0800 h to measure basal corticosterone (Cat # 07120102, MP 
Biomedicals, Solon, Ohio). Mixed trunk blood was also collected at the time of animal 
death (decapitation). All samples were collected in potassium-EDTA coated microvette 
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capillary tubes (Sarstedt, Des Grandes Prairies, Montreal, Québec, Canada, Cat 
#16.444.100), centrifuged at 15,000 rpm for 5 minutes, aliquoted into polyethylene tubes 
and stored at -80°C until further analysis. 
Western Blotting 
Fifty micrograms of protein lysate from epididymal adipose tissue was run on a 
10% (ATGL, HSL, pHSL
ser660
, LPL and GR) or 12% (11β-HSD1) SDS-page gel and 
transferred to a PVDF membrane (Bio-Rad, Canada). Membranes were blocked in 5% 
powdered milk and Tris-buffered saline with Tween 20 (TBST) at room temperature for 
1 hour. Membranes were then incubated overnight in primary antibody at 4°C (ATGL, 
1:500, sc-50223, Santa Cruz Biotechnology, Dallas, TX; HSL, 1:1,000, sc-25843, Santa 
Cruz Biotechnology; pHSL
ser660
, 1:1000, Cat#4126, Cell Signaling, Beverly, MA; LPL, 
1:1500, ab137821, Abcam, Cambridge, MA; GR, 1:1000, sc-8992, Santa Cruz 
Biotechnology; 11β-HSD1, 1:1,000, Cat#10004303, Cayman Chemical Company, Ann 
Arbor, MI). The membranes were then washed with TBST and incubated with goat anti-
mouse (1:10,000, ab6789, Abcam) or goat anti-rabbit (1:10,000, ab6721, Abcam) 
secondary antibodies for 1 hour at room temperature. Membranes were then washed and 
imaged. Images were detected on a Kodak In vivo FX Pro imager and molecular imaging 
software (Carestream Image MI SE, version S.0.2.3.0, Rochester, New York) was used to 
quantify protein content.  For loading controls, α-tubulin (1:40,000, ab7291, Abcam) was 
used for 11β-HSD1 and β-actin (1:20,000, ab6276, Abcam) was used for ATGL, HSL, 
LPL and GR. 
Drug Administration 
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Mifepristone was initially dissolved in dimethyl sulfoxide (DMSO) as a stock 
solution (0.2 g/mL). The mixture was then dissolved further in a vehicle composed of 
0.1% Tween 80 and 0.5% hydroxypropyl methyl cellulose in double distilled water. The 
dilution was adjusted in order to provide a dose of 80 mg/kg body mass of mifepristone 
in a 2 mL/kg body mass solution. This dosing strategy, which is considered to be a high 
dose, was selected based on dosages used in previous rodent studies (169). 
Comparatively, a high dosage for humans is 25 mg/kg body mass (170).  The placebo 
post-WL group received a solution of DMSO + vehicle (placebo) and the mifepristone 
post-WL group received mifepristone + vehicle. Mifepristone and placebo solutions were 
administered once daily via syringe and oral gavage tube (Cat #FTP-18-75, Instech, 
Plymouth, Pennsylvania). Importantly, mifepristone administration did not alter food 
intake compared to the placebo post-WL group. 
Oral glucose tolerance test 
All rats were fasted overnight and administered an oral glucose tolerance test 
(OGTT; 1.5 g/kg body mass) via gavage immediately prior to euthanization. Blood 
glucose was measured at t=0, 5, 15, 30, 60, 90, 120 minutes via a handheld glucometer 
(Bayer, Contour, New York). Blood samples to measure insulin were taken at t=0, 15, 30, 
60, 120 minutes. Glucose and insulin AUC was then measured according to each 
individual rat’s fasting values. 
HOMA Analysis 
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Homeostasis model assessment has been described in detail previously (171). 
Briefly, for insulin resistance (HOMA-IR) was calculated as follows: (Fasted Glucose 
(mM) x Fasted Insulin (mU/L)/22.5). This calculation primarily reflects the relationship 
between hepatic glucose output, insulin secretion, and hepatic resistance to insulin in the 
basal state. Homeostasis model assessment for β-cells (HOMA-β) was calculated as 
follows: (20 x Fasted Insulin (mU/L)/(Fasted Glucose (mM)-3.5). This calculation 
indicates basal pancreatic β-cell function in response to fasted glycemia. 
Statistical Analysis 
All data was analyzed using an appropriate one- or two-way ANOVA with a 
criterion of p<0.05. All significant differences for ANOVA testing will be evaluated 
using a Tukey HSD post-hoc test (GraphPad Prism version 6.03). In each bar graph, a 
different letter denotes a significant difference between groups. All data are mean ± SEM. 
Results 
Cessation of daily running and caloric restriction reduces skeletal muscle mass 
Daily running with caloric restriction for three weeks significantly increased 
soleus and adrenal mass in the control runners versus all other groups (p<0.05, Table 1). 
One week of sedentary behaviour and ad libitum food intake following the three weeks of 
daily exercise and caloric restriction caused a significant reduction in relative plantaris 
and gastrocnemius mass, sedentary versus placebo post-WL (p<0.05, Table 1). Daily 
mifepristone treatment attenuated the reductions in plantaris and gastrocnemius masses.  
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Cessation of daily running and caloric restriction causes rapid body mass gain and 
is attenuated with mifepristone treatment 
All groups that ran during the first three weeks (control runners, placebo and 
mifepristone post-WL) had significantly lower body mass versus the sedentary group 
following 13 days of daily running and remained lower until wheel lock (day 21) 
(p<0.05, Fig. 2A). All groups were provided with 15 grams of standard rodent chow daily 
during the first three weeks of the study. However, relative daily food intake was 
significantly lower in the sedentary group from day 16 until wheel lock (p<0.05, Fig. 2B) 
because these animals weighed more than the other groups. In the post-WL period, the 
placebo post-WL group gained body mass at a faster rate versus the mifepristone post-
WL group and this resulted in a significantly greater final body mass (placebo post-WL 
(318 ± 8.9 g), mifepristone post-WL (290 ± 6.0 g), p<0.05, Fig. 2A and B). A reduction 
in weight gain has also been found with mifepristone administration in mice fed a high-
fat diet when compared to mice only receiving vehicle (169). No differences were found 
in running distances between the three running groups (Fig. 2C and C’). 
11β-HSD1 increases in visceral adipose tissue in response to daily running and is 
reduced by mifepristone 
Three weeks of daily running increased 11β-HSD1 protein content 5-fold in 
epididymal fat (control runners versus sedentary, p<0.05, Fig. 3). 11β-HSD1 remained 
elevated one week following the cessation of daily exercise and caloric restriction in the 
placebo post-WL group versus sedentary. (p<0.05, Fig. 3A). Daily mifepristone 
administration significantly reduced 11β-HSD1 content during the post-WL period 
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(mifepristone post-WL versus control runners, placebo post-WL, p<0.05, Fig. 3). GR 
protein content did not differ between any groups in epididymal fat (Fig. 3B). 
Mifepristone does not alter markers of lipolysis in visceral adipose tissue 
Three weeks of daily running increased pHSL
ser660
 and total HSL 2-fold, and 
ATGL 4-fold in control runners versus sedentary in epididymal fat (p<0.05) (Fig. 4A, B 
and C). One week of sedentary behaviour and ad libitum food intake reduced pHSL
ser660
 
~7-fold, total HSL 2-fold and ATGL 4-fold versus control runners (p<0.05) The protein 
content of pHSL
ser660
, total HSL and ATGL were unaltered by mifepristone 
administration. pHSL
ser660 
was also significantly reduced in placebo and mifepristone 
post-WL below levels of the sedentary group (p<0.05). Three weeks of daily running 
caused a small but non-significant reduction in LPL content in epididymal fat versus the 
sedentary group. Cessation of daily running and caloric restriction caused a 2-fold 
increase in LPL content and was unaltered by mifepristone treatment (p<0.05) (Fig. 4D). 
Cessation of daily running and caloric restriction causes glucose intolerance, insulin 
resistance, and is attenuated by mifepristone 
One week of sedentary behaviour and ad libitum food intake following three 
weeks of daily wheel running and caloric restriction impaired glucose tolerance and 
raised blood glucose levels both in the fasted state (Fig. 6A) and at multiple time points 
during an OGTT (Fig. 5A). The cumulative area under the curve (AUC) for the glucose 
concentration response to oral glucose gavage significantly increased 1.8-fold in the 
placebo post-WL group (238.3 ± 16.3) versus control runners (133.1 ± 25.8) (p<0.05). 
This impairment in glucose tolerance was prevented in the mifepristone post-WL group 
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(139.2 ± 11.2) (p<0.05 versus placebo post-WL, Fig. 5A’). The glucose AUC of the 
placebo post-WL group was the same as rats that were sedentary and had ad libitum food 
intake for the entire study (sedentary ad lib, 229 ± 19.8)  (Supplementary Fig. 3B), 
despite significantly less cumulative food intake in the placebo post-WL group 
(Supplementary Fig. 2). Thus, the improvements in glucose tolerance in response to daily 
wheel running and caloric restriction are eliminated after only one week of sedentary 
behaviour and reintroduction to ad libitum feeding. 
There were greater insulin concentrations both in the fasted state (Fig. 6B) and 
during an OGTT (Fig. 5B) in the placebo post-WL group compared to all other groups. 
The placebo post-WL group (193.2 ± 33.8) demonstrated an 8-fold increase in insulin 
AUC versus control runners (23.4 ± 6.4) and this elevated response, suggesting insulin 
resistance, was attenuated in the mifepristone post-WL group (72.1 ± 9.2) (p<0.05 versus 
placebo post-WL, Fig. 5B’). 
Cessation of daily running and caloric restriction impairs homeostasis model 
assessment and is prevented by mifepristone 
Homeostasis model assessment of insulin resistance (HOMA-IR) primarily 
reflects hepatic insulin resistance in the basal state and takes into account the fasted 
plasma glucose (FPG) and fasted plasma insulin (FPI) values. There was a significant 
increase in the placebo post-WL group for fasting glucose (6.12 ± 0.29 mM) and insulin 
(1.89 ± 0.28 ng/mL) concentrations versus control runners (4.4 ± 0.22 mM glucose, 0.25 
± 0.05 ng/mL insulin) (p<0.05; Fig. 6A, p<0.01; Fig. 6B). These increases were 
attenuated in the mifepristone post-WL group (4.94 ± 0.19 mM glucose, 0.60 ± 0.11 
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ng/mL insulin) and were significantly lower than in the placebo post-WL group (p<0.05). 
The placebo post-WL group (14.88 ± 2.31) had an extensive 10-fold increase in insulin 
resistance versus control runners (1.46 ± 0.36) and this was abolished in the mifepristone 
post-WL group (3.66 ± 0.77) (p<0.01, Fig 6D). 
Homeostasis model assessment of β-cell function (HOMA-β) measures the insulin 
secretory function of β-cells and also takes into account FPG and FPI. There was a small 
but non-significant increase in relative β-cell function in the placebo post-WL group 
(1.59 ± 0.23) versus control Runners (0.76 ± 0.20) (Fig. 6C). These data indicate that 
insulin resistance in the fasted state occurs following cessation of daily running and 
caloric restriction, it is uncompensated by alterations in β-cell function, and it can be 
prevented by antagonism of GRs by mifepristone. 
Rapid adiposity rebound occurs following cessation of regular caloric restriction 
and exercise and is attenuated by mifepristone 
Three weeks of voluntary running significantly reduced relative fat mass in 
perirenal (0.196 ± 0.02 g), epididymal (0.86 ± 0.09 g), and inguinal (0.30 ± 0.06 g) 
depots in control runners versus sedentary (perirenal; 0.42 ± 0.07 g, epididymal; 2.64 ± 
0.30 g, inguinal; 1.88 ± 0.22 g) (p<0.05, Fig. 7A, B, and C). One week of sedentary 
behaviour and ad libitum feeding following three weeks of daily running and caloric 
restriction resulted in a significant rebound in relative adiposity in perirenal (0.91 ± 0.04 
g), epididymal (4.48 ± 0.17 g), and inguinal (3.28 ± 0.32 g) depots in the placebo post-
WL group versus control runners (p<0.05, Fig. 7A, B, and C). This relative adiposity 
rebound phenomenon was significantly attenuated in the perirenal (0.64 ± 0.07 g) and 
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inguinal (2.11 ± 0.20 g) depots in the mifepristone post-WL group versus placebo post-
WL (p<0.05, Fig. 7A and C). Mifepristone also attenuated relative epididymal fat mass in 
placebo versus mifepristone post-WL (p=0.07). This suggests that GC signaling in the 
post-WL period may contribute to increasing adipose tissue mass and this can be reduced 
by a GR antagonist. The combination of daily running plus caloric restriction versus only 
caloric restriction for three weeks did not result in any differences in relative adiposity 
following the one week sedentary ad libitum period (Supplementary Fig. 4). Thus, the 
addition of exercise did not predispose rats to further adiposity rebound versus caloric 
restriction alone.  
Basal corticosterone is increased by exercise and caloric restriction 
Corticosterone measurements were made on day 0 before the rats were divided 
into respective groups and a basal AM value of 117.3 ± 28.3 ng/mL was found for all of 
the rats (Fig. 8). Ten days into the protocol there was a significant increase in AM 
corticosterone concentrations in all the runner animals combined (359.6 ± 54.0 ng/mL) 
versus day 0 values (p<0.05) and a trend for an increase in the sedentary animals (288.7 ± 
98.5 ng/mL). On day 20, both sedentary (390.8 ± 40.5 ng/mL) and all runners (336.3 ± 
48.2 ng/mL) had significantly greater AM corticosterone concentrations versus day 0 
values (p<0.05). Cessation of regular exercise and caloric restriction significantly reduced 
basal corticosterone in both the placebo post-WL (48.0 ± 25.8 ng/mL) and mifepristone 
post-WL group (56.4 ± 18.1 ng/mL) versus sedentary and all runners on day 20 (p<0.05, 
Fig. 8). Despite antagonism of GC receptors in the mifepristone post-WL group after 
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cessation of regular exercise and caloric restriction there was no difference in 
corticosterone versus placebo post-WL. 
Oxidative capacity improves with exercise but is not altered by Mifepristone 
Skeletal muscle oxidative capacity was qualitatively assessed by succinate 
dehydrogenase histology in the tibialis anterior (Fig. 9). Exercise increased the intensity 
of staining for succinate dehydrogenase indicating improved oxidative capacity and 
mitochondrial content. One week of sedentary behaviour and ad libitum feeding did not 
appear to result in reduced mitochondrial content as staining intensity in the placebo and 
mifepristone post-WL groups remained similar to the control runners. 
Discussion 
In the current study, we have demonstrated that one week of sedentary behaviour 
and ad libitum food intake following three weeks of daily voluntary wheel running and 
caloric restriction resulted in a rapid impairment in insulin sensitivity, glucose tolerance 
and a rapid rebound in adipose tissue growth. A major finding from this study was that 
daily oral administration of mifepristone, a GR antagonist, attenuated, prevented, or 
reversed all of the detrimental metabolic effects that were observed. Whole-body insulin 
sensitivity and glucose intolerance were preserved, significantly less adipose tissue was 
gained and body mass was lower despite no difference in food intake versus the placebo 
post-WL group (Fig. 2). Interestingly, this reduced quantity of adipose mass in the 
mifepristone treated group did not appear to be related to increased lipase expression 
following mifepristone treatment, but rather it was associated with a reduction in 11β-
HSD1 content in visceral adipose tissue. These findings suggest that elevations in GC 
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action following regular exercise and caloric restriction promote rapid deterioration in 
metabolic control in healthy organisms and that this deterioration can be inhibited by a 
GC receptor antagonist. 
Insulin Sensitivity 
A novel finding of this study is that these rapid impairments in whole-body 
insulin sensitivity that occur following reduced daily physical activity and increased food 
intake appears to be influenced by stress hormones. One week of reduced physical 
activity and ad libitum food intake following three weeks of daily exercise and caloric 
restriction caused a striking impairment in glucose tolerance and whole-body insulin 
sensitivity. During the oral glucose tolerance test in our model, the placebo post-WL 
group exhibited a 1.8-fold and 8.3-fold increase in glucose AUC and insulin AUC, 
respectively versus control runners (Fig. 5). Additionally, fasting blood glucose was 
nearly 2 mM higher, fasting insulin was 7-fold higher and insulin resistance, as measured 
by HOMA-IR, was 7-fold higher in placebo post-WL versus control runners (Fig. 6). 
Daily administration of mifepristone prevented hyperglycemia and hyperinsulinemia 
during the oral glucose tolerance test (Fig. 5) as well as reduced fasting blood glucose 
and insulin versus placebo post-WL (Fig. 6). Additionally, the increase in HOMA-IR 
found in the placebo post-WL group was prevented in the mifepristone post-WL group. 
Collectively, these findings support that factors which regulate GC action, including 
circulating abundance of GCs, 11β-HSD1, and the GR may play a significant role in the 
rapid development of insulin resistance that ensues following reduced physical activity 
and excess caloric intake. 
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In particular, we found that the placebo post-WL group had a 5-fold greater 
abundance of 11β-HSD1 protein in epididymal fat versus mifepristone post-WL although 
no difference was found in GR protein content (Fig. 3). 11β-HSD1 increases intracellular 
GC availability via the conversion of inactive cortisone to active cortisol in humans (11-
dehydrocorticosterone to corticosterone in rodents). Overexpression of 11β-HSD1 within 
adipose tissue increases intracellular GC abundance, promotes visceral adiposity, whole-
body insulin resistance, glucose intolerance, as well as increased serum FFAs and 
triglycerides (121). Importantly, studies have shown that GCs and insulin stimulate both 
the activity and expression of 11β-HSD1 (116, 172, 173). This feed-forward phenomenon 
of GCs and 11β-HSD1 has been demonstrated both in vivo and in vitro (174, 175). This 
is an important characteristic of the regulation of 11β-HSD1 as the development of 
hyperinsulinemia, which we observed following reduced physical activity, could initiate a 
cycle of increased 11β-HSD1, further visceral intracellular hypercortisolism followed by 
exacerbation of insulin resistance. Furthermore, we found a 3-fold increase in circulating 
corticosterone throughout the first three weeks in all of the exercising rats (Fig. 8). Thus, 
immediately prior to the sedentary ad libitum period, there was systemic 
hypercortisolism. In combination with the hyperinsulinemia, this may have contributed to 
the increased abundance of 11β-HSD1 protein which was observed. This is supported by 
our finding that blockage of GC action with mifepristone significantly reduced 11β-
HSD1 and prevented fasted hyperinsulinemia. 
What remains puzzling is the function of this increased 11β-HSD1 protein content 
in visceral adipose tissue in wheel running rats. Despite the substantial evidence in 
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support of a role of elevated 11β-HSD1 in the pathogenesis of MetS and visceral obesity, 
we have found increased activity and content of 11β-HSD1 in visceral fat following 
regular exercise to be associated with improved metabolic health (161, 163, 164). Thus, 
increased intracellular visceral GC exposure correlates with both impaired and improved 
metabolic health. Whether the resulting phenotype is impaired or improved, metabolic 
health appears to be most closely related to the amount of daily physical activity 
undergone by the organism.  
Both chronic exogenous and endogenous GC exposure are well known to induce 
insulin resistance in both humans and rodents (176-178) as well as contribute to the 
development of MetS (121). However, although GCs impair whole-body insulin 
sensitivity, this does not necessarily indicate impaired insulin action in all tissues. 
Previous studies by Booth and colleagues have found that impaired insulin sensitivity 
occurs in skeletal muscle but not adipose tissue shortly following wheel lock in rodents 
(14, 19). Impressively, only 53 hours post-WL after having exercised daily for three 
weeks, there is a significant 37% reduction in insulin-stimulated 2-deoxyglucose uptake 
by the epitrochlearis muscle when compared to values found in rats that had their wheels 
locked for only 5 hours (19). Resultantly, 53 hours after wheel lock, 2-deoxyglucose 
uptake was comparable to those of rats that had never exercised. This reduction in 
glucose transport was concurrently associated with a 29 to 34% reduction in insulin 
receptor (IR) protein, IR
tyr
 phosphorylation, Akt
ser473
 phosphorylation, as well as GLUT4 
protein content in skeletal muscle (19). In contrast, isolated epididymal adipocytes 
remain insulin-sensitive at 29 and 53 hours following wheel lock in rodents (14). 
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Interestingly, several studies have found that both exogenous and endogenous GC 
exposure increase rather than impair insulin signaling in adipose tissue (179-181). For 
instance, despite inducing whole-body and hepatic insulin resistance, overnight 
intravenous hydrocortisone infusion in humans resulted in enhanced insulin action in 
adipose tissue (181). GCs either improving insulin sensitivity or failing to cause insulin 
resistance in adipocytes despite inducing whole-body insulin resistance and 
hyperinsulinemia could be a potential mechanism underlying the rapid growth of adipose 
tissue we observed due to excessive stimulation of lipogenesis. Thus, there are tissue-
specific impairments at multiple levels within the insulin signaling pathway that occur 
shortly following initiation of physical inactivity and skeletal muscle appears to be the 
most detrimentally affected in terms of impaired insulin sensitivity. 
Insulin sensitivity and glucose tolerance are consistently compromised following 
reduced daily physical activity. This strongly indicates that fluctuations in physical 
activity significantly contribute to the day-to-day preservation of glycemic control. 
Interestingly, a single bout of running or cycling for 45 minutes following ten days of bed 
rest significantly improves and nearly restores glycemic response to baseline 
measurements in humans (41). However, returning to normal ambulation without 
organized bouts of exercise does not restore glycemic response until two weeks after bed 
rest (182). This demonstrates the ease with which healthy individuals can cycle through 
periods of glucose tolerance and intolerance based on their current level of daily physical 
activity. Importantly, evidence from healthy humans suggests that extensive blood 
glucose oscillation can have even more damaging effects than chronic hyperglycemia on 
54 
 
endothelial cell function and generation of reactive oxygen species (42) and this may 
participate in the pathogenesis of type 2 diabetes (43). 
Adiposity rebound 
Not only does the quantity of visceral fat mass correlate closely with metabolic 
and cardiovascular complications (46, 47), but it also exhibits great plasticity in response 
to exercise and dietary interventions. We observed a 4- to 5-fold increase in relative 
adipose mass in perirenal and epididymal fat and a 10-fold increase in inguinal fat after 
one week of sedentary behaviour and ad libitum feeding following three weeks of daily 
wheel running and caloric restriction (Fig. 7). These data extend the findings by Booth 
and Thyfault (14) where as early as 53 hours following three weeks of daily running in 
rats there was a significant 25 and 48% increase in relative epididymal and omental fat, 
respectively. In another study by this group, daily voluntary running was shown to 
significantly lower body fat percentage and total body fat but one week following wheel 
lock both indices were rapidly restored to levels found in animals that had remained 
sedentary throughout the study (17).  In our study, we found that blocking the action of 
GCs with mifepristone significantly attenuated this rapid adipose mass rebound 
phenomenon. This suggests that during the sedentary ad libitum period, GCs may 
collectively be acting in an adipogenic, lipogenic or anti-lipolytic manner either directly 
or indirectly to increase the storage of lipids within visceral adipose tissue. Consequently, 
mifepristone administration likely resulted in either less lipid production or increased 
lipid breakdown. In terms of lipolysis this is initially counterintuitive due to the well-
established role of GCs on increasing lipolysis. Twenty-four hours to ten days of 
exposure to dexamethasone, cortisone, cortisol or corticosterone have all shown to 
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increase lipolysis in adult adipocytes (83, 84). This occurred in tandem with increased 
mRNA expression of ATGL and total HSL as well as increased protein content of ATGL 
and greater phosphorylation of HSL on the activating sites Ser563 and Ser660. In 
addition, this elevated rate of lipolysis was abolished by co-treatment with the GR 
antagonist mifepristone (83, 84). In the current study, we found a significant increase in 
total HSL, pHSL
ser660
, and ATGL protein content in response to daily voluntary wheel 
running followed by a 2- to 4-fold reduction in their content after one week of sedentary 
behaviour and ad libitum feeding (Fig. 4). However, mifepristone administration did not 
alter their protein content versus the placebo group. Furthermore, we also found no 
obvious difference in relative oxidative capacity of skeletal muscle, as measured by 
succinate dehydrogenase histology, in placebo versus mifepristone post-WL (Fig. 9). 
Thus our data suggest that an increase in lipolysis within adipose tissue as well as 
increased oxidative capacity in skeletal muscle did not likely contribute substantially to 
the reduced adipose tissue rebound in the mifepristone treatment group. 
Importantly, although GCs play a role in increasing lipolysis, they can also cause 
adipose tissue growth, particularly visceral, as well as induce insulin resistance and 
hyperinsulinemia. Within adipocytes, insulin stimulates the production of sterol 
regulatory element binding protein 1c which regulates the transcription of a variety of 
different lipogenic genes including fatty acid synthase, acyl-CoA carboxylase, and 
glycerol-3-phosphate acyltransferase (183). Insulin also potently inhibits basal and 
catecholamine-mediated lipolysis by activation of phosphodiesterase-3B and consequent 
catalysis of cAMP, reduced PKA activation and reduced stimulation of HSL. Therefore it 
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is plausible that the hyperinsulinemia in our study that was induced by cessation of daily 
wheel running and caloric restriction dominates lipid metabolism to result in excessive 
lipogenesis and inhibition of lipolysis. As early as 10 hours following wheel lock in 
rodents there is a ~3- to 4-fold rise in epididymal TG synthesis when compared to 
sedentary animals, an effect that remained elevated to a similar extent at 53 hours post-
WL (14). Furthermore, there is a 1.5- and 3-fold increase in mtGPAT activity and 
expression, respectively, 10 to 53 hours post-WL (15). The protein mtGPAT is crucial for 
the acylation of glycerol-3-phosphate to lysophosphatidic acid and subsequent TG 
synthesis (68). Thus, there appears to be a rapid increase in lipid synthesis in adipose 
tissue immediately following initiation of sedentary behaviour and these elevations can 
persist when sedentary behaviour is prolonged.  
This suggests that the attenuated growth of epididymal fat which occurred in the 
mifepristone post-WL group was not due to greater lipolysis in this depot. Due to the 
reduction in energy expenditure and hyperphagic food intake following cessation of daily 
running and reintroduction to ad libitum food availability in our study, it is likely that 
lipogenic processes dominate in adipose tissue. Future research should investigate 
whether mifepristone administration attenuated adipose tissue growth by limiting 
lipogenesis. 
Importantly, GCs also stimulate adipogenesis (69, 167, 168). This is supported by 
data which found that despite a significant increase in adipose tissue lipolysis in rats 
treated for 10 days with corticosterone, they exhibited a 1.5-fold increase in epididymal 
adipose mass and a 2.5-fold increase in number of adipocytes per mg of tissue (83). Thus, 
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GCs can concurrently contribute to both the breakdown of lipids as well as the 
accumulation of new adipocytes. Interestingly, the main contribution to the immediate (≤ 
53 hours) adiposity rebound in wheel-locked rodents is mediated by an 18% increase in 
mean adipocyte volume as opposed to increased cell number (15). However, more recent 
studies that tracked the wheel lock period for up to 1 week, reported that the rapid accrual 
of epididymal, omental, retroperitoneal, as well as perirenal fat was primarily due to 
hyperplasia of adipocytes rather than hypertrophy (16, 18). Future studies are needed to 
confirm if less adipose hyperplasia and TG synthesis occurs following treatment with a 
GR antagonist during a period of reduced physical activity and whether or not this 
contributes to the attenuated adipose tissue accumulation. 
Conclusion 
In conclusion, reducing daily physical activity in rodents rapidly promotes 
expansion of adipose tissue depots and a deterioration of whole-body insulin sensitivity 
and glucose tolerance. These findings coincide with data from human studies which have 
documented impaired insulin sensitivity, glucose tolerance and visceral fat expansion 
following reduced physical activity through either bed rest or reduced daily step count (8, 
9, 11, 12). Thus, despite the specific intervention, the reproducibility and similarity of 
their consequences are striking. Consequently, adopting a lifestyle of intermittent periods 
of sedentary behaviour and fluctuating caloric intake may precipitate the development of 
cardiometabolic disease over time. We also demonstrate in this study, for the first time, 
that the actions of stress hormones during periods of reduced physical activity and 
increased caloric may be linked to the deterioration in metabolic health. At the very least, 
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many of the deleterious metabolic effects of stopping caloric restriction and exercise can 
be blocked or at least attenuated by the global glucocorticoid receptor antagonist 
mifepristone. Although the mechanisms for the benefits for mifepristone are not entirely 
clear, reductions in 11β-HSD1 expression in adipose tissue appear to be associated with 
improved metabolic health this animal model of cessation of daily exercise and caloric 
restriction. Further studies are needed to determine the molecular mechanisms underlying 
the contribution of stress hormones to this adiposity rebound phenomenon, rapidly 
impaired glucose tolerance and insulin sensitivity. 
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TABLES AND FIGURES                                      5 
 
Table 1. Tissue masses 
 
Skeletal muscle and liver masses relative to body mass (g/kg body mass); Adrenal mass relative to 
body mass (mg/kg body mass). Post-wheel lock (post-WL). Different letter indicates a significant 
difference (p<0.05). All data are mean ± SEM; n=8-10 for skeletal muscle and liver; n=3-4 for 
adrenals. 
 
 
 
 
 
 
 
 
 
 
 Sedentary Control Runners Placebo post-WL Mifepristone post-WL 
Tibialis anterior  1.97 ± 0.05
a 1.95 ± 0.06
a 1.78 ± 0.02
b 1.79 ± 0.03
b 
Plantaris 0.96 ± 0.04
a 0.90 ± 0.03
ab 0.86 ± 0.02
b 0.90 ± 0.02
ab
 
Soleus 0.45 ± 0.02
a
 0.54 ± 0.02
b
 0.45 ± 0.01
a
 0.45 ± 0.02
a
 
Gastrocnemius 5.23 ± 0.13
a
 4.96 ± 0.12
ab
 4.67 ± 0.11
b
 4.86 ± 0.11
ab
 
Liver 30.2 ± 0.36
a
 30.7 ± 1.48
a
 35.9 ± 1.25
b
 37.9 ± 1.27
b 
Adrenals 76.6 ± 3.44
a
 102.3 ± 5.48
b
 78.8 ± 4.32
a
 75.3 ± 1.41
a
 
60 
 
 
 
 
 
 
 
 
Figure 1. Experimental timeline.  Sprague-Dawley rats were divided into 4 different 
groups; sedentary, control runners, placebo post-WL, and mifepristone post-WL. All 
groups were placed on a calorie restricted diet (15 g/day) and all rats except for the 
Sedentary group were given access to voluntary running wheels 24h/day for 21 days. 
Basal (AM) corticosterone (CORT) measurements were taken on days 0, 10, 20 and 25. 
On day 21, the placebo and mifepristone post-WL groups had their wheels locked, were 
reintroduced to ad libitum feeding, and were given daily oral gavage either with or 
without drug (mifepristone). The sedentary and control runner groups were harvested on 
day 21 and used at pre-wheel lock comparisons. The placebo and mifepristone post-WL 
groups were harvested on day 28, one week following cessation of regular exercise and 
caloric restriction. All groups had an oral glucose tolerance test (OGTT) administered on 
the day of harvest. 
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Sedentary 
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Figure 2. Body mass, food intake, and running data. (A) Body mass increases over 
time in all groups. All groups were calorie restricted during the first three weeks (15 
g/day). At the end of the 3
rd
 week, the placebo and mifepristone post-wheel lock (post-
WL) groups had their wheels locked and were reintroduced to ad libitum feeding. The 
sedentary and control runner groups were harvested and used as pre-wheel lock 
comparisons. (B) Relative daily food intake during the caloric restriction (Week 1-3) and 
ad libitum (Week 4) periods. (C and C’) Daily and total running distance throughout 
protocol in all 3 running groups. *, sedentary vs. all other groups (p<0.05). #, placebo 
post-WL vs. mifepristone post-WL (p<0.05). All data are mean ± SEM. n=8-10. 
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Figure 3. Visceral adipose tissue glucocorticoid exposure. Relative 11β-HSD1 and GR 
protein expression in epididymal fat. Post-wheel lock (post-WL). Different letter 
indicates a significant difference (p<0.05). All data are mean ± SEM. n=4-6. 
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Figure 4. Visceral adipose tissue lipolytic markers. Relative pHSL
ser660
, total HSL, 
ATGL and LPL protein expression in epididymal fat. Post-wheel lock (post-WL). 
Different letter indicates a significant difference (p<0.05). All data are mean ± SEM. 
n=5-8. 
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Figure 5. Glucose tolerance. All groups had an oral glucose tolerance test (OGTT) 
administered (1.5 g/kg body mass) at either the end of the 3
rd
 (sedentary and control 
runners) or 4
th
 week (placebo and mifepristone post-wheel lock (post-WL)) (A) Glucose 
concentrations (mM) in the fasted state (t=0) and at t=5, 15, 30, 60, and 120 minutes post 
oral glucose load. (B) Insulin concentrations (ng/mL) in the fasted state (t=0) and at t=15, 
30, 60, and 120 minutes. (A’ and B’) Area under the curve (AUC) for glucose and insulin 
during the OGTT was calculated relative to the t=0 glucose or insulin value for each 
individual rat. Different letter indicates a significant difference (p<0.05). All data are 
mean ± SEM. n=8-10. 
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Figure 6. β-cell function and insulin resistance. (A and B) Fasted glucose and insulin 
values taken at the end of the 3
rd
 (sedentary and control runners) or 4
th
 week (placebo and 
mifepristone post-wheel lock (post-WL)). (C) Relative HOMA-β was calculated as 
follows: [20 x Insulin (mU/L)]/[Glucose (mM) – 3.5]. (D) HOMA-IR was calculated as 
follows: [Insulin (mU/L) x Glucose (mM)]/[22.5]. Different letter indicates a significant 
difference (p<0.05 for A, p<0.01 for B and D). All data are mean ± SEM. n=8-10. 
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Figure 7. Adipose tissue mass.  Perirenal, epididymal, and inguinal fat pads were 
harvested at the end of the 3
rd
 (sedentary and control runners) or 4
th
 week (placebo and 
mifepristone post-wheel lock (post-WL)). Different letter indicates a significant 
difference (p<0.05). All data are mean ± SEM. n=8-10. 
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Figure 8. Basal corticosterone. AM corticosterone (0800 h) concentrations were 
collected on days 0, 10, 20 and 25 from the saphenous vein. Day 0 represents all rats 
before they were divided into separate groups. Day 10 represents the mid-way point of 
the caloric restriction ± daily voluntary running pre-wheel lock portion of the protocol. 
Day 25 represents the post-wheel lock (post-WL) period. Different letter indicates a 
significant difference (p<0.05). All data are mean ± SEM. n=3-4 for sedentary, placebo 
and mifepristone post-WL. n=11-15 for ‘all groups’ and ‘all runners’. 
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Figure 9. Oxidative capacity in skeletal muscle. Representative succinate 
dehydrogenase histology in the tibialis anterior. 
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SUMMARY AND FUTURE DIRECTIONS        6 
 
Summary: 
 In this thesis project, we investigated the effects of cessation of regular voluntary 
wheel running and caloric restriction on the rapid development of glucose intolerance, 
insulin resistance and adipose tissue growth. Elevated 11β-HSD1 within adipose tissue is 
well-known to be associated with insulin resistance and central adiposity. In contrast, our 
laboratory has previously found elevations of 11β-HSD1 activity and content in visceral 
adipose tissue following regular exercise and this was associated with improvements in 
metabolic health. Based on this divergence of association of 11β-HSD1 with improved or 
impaired metabolic health, we hypothesized that sustained elevations in 11β-HSD1 may 
predispose animals to the rapid impairments in glucose tolerance, insulin sensitivity and 
adipose tissue growth that is found following cessation of regular exercise 
(Supplementary Fig. 5). 
 Confirming earlier studies, we found that daily voluntary wheel running increased 
11β-HSD1 content in epididymal fat. Additionally, cessation of wheel running and 
caloric restriction caused glucose intolerance, insulin resistance and rapid adipose tissue 
growth. We found that daily oral administration of mifepristone, a GR antagonist, greatly 
attenuated the impairments found in glucose tolerance and insulin sensitivity. In addition, 
mifepristone reduced the amount of both adipose tissue growth and body growth that 
occurred following cessation of daily running and caloric restriction. This study has 
identified a potential role of GCs in being causative agents towards the impairment in 
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metabolic health that ensues after transitioning to lower amounts of daily physical 
activity and increased food intake. 
Limitations and Future Directions: 
Importantly, mifepristone is a non-selective glucocorticoid receptor antagonist 
and it competitively binds with both the GR and PR (144). Because of this, we cannot 
rule out the influence of the PR in our study. Although we have identified a role of GCs 
in impairing metabolic health following reduced physical activity and elevated food 
intake, the specific mechanisms and which tissues are involved remains undetermined. In 
this study, we found that treatment with mifepristone caused a reduction in 11β-HSD1 
within visceral adipose tissue. However, based on these findings we inferred that visceral 
adipose tissue in the placebo post-WL group had elevated production and concentration 
of GCs compared to the mifepristone group. We did not measure adipose tissue GC 
concentrations or release of GCs from adipose tissue into circulation. In terms of 
alterations in adipose tissue lipolysis in the different groups we inferred the relative 
content of lipolytic enzymes to correspond to relative lipolysis. To more accurately assess 
lipolytic rates and verify that it did not play a role in the attenuation of adipose tissue 
growth in the mifepristone post-WL versus placebo post-WL groups, future studies 
should analyze basal and/or stimulated lipolysis ex vivo. Additionally, considering that in 
the post-WL period of this study, the mifepristone and placebo groups were expending 
less energy and consuming greater calories per day, it may be more appropriate for future 
studies to investigate if mifepristone attenuated the production of new lipids via 
lipogenesis and/or adipogenesis. We also investigated skeletal muscle oxidative capacity 
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by only qualitative means. More analysis is needed to confirm if our findings of no visual 
differences in staining intensity between the mifepristone post-WL and placebo post-WL 
groups in SDH are valid. The data we have collected thus far points to 11β-HSD1 as a 
possible contributor to the rapid impairments in metabolic health and adipose tissue 
growth that occurs after transitioning from high to low levels of daily physical activity. 
To establish this connection, future studies should investigate if treatment with an 11β-
HSD1 inhibitor also attenuates the impairments in metabolic health we observed. 
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APPENDIX                                                              6 
Appendix A: Supplementary Figures 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Experimental timeline.  Sprague-Dawley rats were divided 
into six different groups; sedentary ad lib, sedentary CR, sedentary post-CR, control 
runners, placebo post-wheel lock (post-WL), and mifepristone post-WL. All groups 
except sedentary ad lib were placed on a calorie restricted diet (15 g/day) with or without 
access to voluntary running wheels 24h/day for 21 days. On day 21, the sedentary post-
CR, placebo and mifepristone post-WL groups were reintroduced to ad libitum feeding. 
Placebo and mifepristone post-WL had their wheels locked and were given daily oral 
gavage either with or without drug (mifepristone). The sedentary CR and control runner 
groups were harvested on day 21 and used as pre-wheel lock comparisons. The placebo 
and mifepristone post-WL groups were harvested on day 28, one week following 
cessation of regular exercise and caloric restriction. All groups had an oral glucose 
tolerance test (OGTT) administered on the day of harvest. 
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Supplementary Figure 2. Body mass, food intake, and running data. (A) Body mass 
throughout the study. (B) Daily fluctuations in food intake relative to body mass. (C) 
Average daily food intake. Post-wheel lock (post-WL). Post-caloric restriction (post-CR). 
Different letter indicates a significant difference (p<0.05) All data are mean ± SEM. n=5-
10. 
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Supplementary Figure 3. Glucose tolerance. All groups had an oral glucose tolerance 
test (OGTT) administered (1.5 g/kg body mass) at either the end of the 3
rd
 (sedentary CR 
and control runners) or 4
th
 week (all other groups) (A) Glucose concentrations (mM) in 
the fasted state (t=0) and at t=5, 15, 30, 60, and 120 minutes post oral glucose load. (B) 
Area under the curve (AUC) for glucose during the OGTT was calculated relative to the 
t=0 glucose value for each individual rat. Post-wheel lock (post-WL). Post-caloric 
restriction (post-CR). Different letter indicates significant difference (p<0.05). All data 
are mean ± SEM. n=5-10. 
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Supplementary Figure 4. Adipose tissue mass.  Perirenal, epididymal, and inguinal fat 
pads were harvested at the end of the 3
rd
 (sedentary CR and control runners) or 4
th
 week 
(all other groups). Post-wheel lock (post-WL). Post-caloric restriction (post-CR). 
Different letter indicates a significant difference (p<0.05). All data are mean ± SEM. 
n=5-10. 
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Supplementary Figure 5. Summary of findings. Daily exercise and caloric restriction 
led to reduced visceral fat, improved insulin sensitivity and increased GC exposure 
within epididymal fat. Cessation of regular voluntary wheel running and reintroduction to 
ad libitum food intake led to rapid gains in visceral fat, insulin resistance and glucose 
intolerance with sustained elevations of GC exposure within epididymal fat. With daily 
mifepristone treatment there was an attenuation of visceral fat growth, complete retention 
of glucose tolerance and insulin sensitivity, and GC exposure within epididymal fat was 
reduced. 
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